Clinicians play a key role in ensuring early and accurate Alzheimer's disease diagnosis, as well as access to treatments and quality care. Understanding amyloid-targeting antibodies for the treatment of Alzheimer's can help patients and their caregivers improve quality of life.
The amyloid-targeting therapies on this page target and remove beta-amyloid from the brain and reduce cognitive and functional decline in people living with early Alzheimer's, including people living with mild cognitive impairment (MCI) or mild dementia due to Alzheimer's disease.
Donanemab (Kisunla™)
Donanemab (Kisunla) is an anti-amyloid antibody intravenous (IV) infusion therapy delivered every month. It has received traditional approval from the FDA to treat early Alzheimer's disease, including people living with mild cognitive impairment (MCI) or mild dementia due to Alzheimer's disease who have confirmation of elevated beta-amyloid in the brain.
Developed by the manufacturer and the FDA.
Lecanemab (Leqembi®)
Lecanemab (Leqembi) is an anti-amyloid antibody intravenous (IV) infusion therapy that is delivered every two weeks. It received traditional approval from the FDA to treat early Alzheimer's disease, including people living with mild cognitive impairment (MCI) or mild dementia due to Alzheimer's disease who have confirmation of elevated beta-amyloid in the brain.
Developed by the manufacturer and the FDA.
Lecanemab – Clinician Toolkit
Developed by the Alzheimer's Association.
Shared with permission from Mayo Clinic Rochester, Department of Neurology.
Shared with permission from Mayo Clinic Rochester, Department of Neurology.
For more information
For information about approved and available Alzheimer's disease treatments, contact the Alzheimer's Association Health Systems and Medical Professionals team using .